ProQR Therapeutics has priced a $50 million underwritten registered direct offering of 27.6 million shares at $1.81 each, alongside a concurrent private placement of 5.1 million shares to Eli Lilly for $9.2 million. The funds will support ProQR's RNA therapy research and clinical development using its proprietary Axiomer RNA editing platform. The offering is expected to close around June 26, 2026, with proceeds aimed at advancing their pipeline and general corporate purposes. This financing strengthens ProQR's ability to develop transformative RNA medicines for rare and common diseases.
Eli Lilly has finalized its acquisition of Centessa Pharmaceuticals, a company developing orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders. This acquisition strengthens Lilly's neuroscience portfolio, aiming to address severe ...
President Trump highlighted the creation of over 2,600 manufacturing jobs in Pennsylvania during a visit to the Mack Trucks facility. He credited his administration's policies, including rolling back stringent fuel emissions regulations, for boosting...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Illumina appointed Dr. Daniel M. Skovronsky, Chief Scientific and Product Officer at Eli Lilly, to its Board of Directors. His expertise in drug discovery and clinical development aligns with Illumina's focus on genomics and multiomics innovation. Th...
New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76%...
